exon 19 duplication . what treatment

Portal Forums Lung/Thoracic Cancer NSCLC Stage IV NSCLC exon 19 duplication . what treatment

This topic contains 1 reply, has 2 voices, and was last updated by JimC Forum Moderator JimC Forum Moderator 2 months, 4 weeks ago.

Viewing 2 posts - 1 through 2 (of 2 total)
Author Posts   
Author Posts
May 19, 2018 at 8:11 am  #1294431    


Good dat. Wife diagnose with stage 4 lung cancer last october. done targeted treatment with tagrisso from 07 nov 2017, due to egfr exon 19 duplication. during 1st month tumour shrink but not significant and stop taking tagrisso since 20 march this year as doctor advice tumour is immune to the treatment. suggest go for chemo but wife afraid and went for a natural healing process. last pet scan on 14 may 2018 and tumour grows with met to bones, liver and kidney. What shud be the next course of action. Thank you

May 19, 2018 at 8:40 pm  #1294433    
JimC Forum Moderator
JimC Forum Moderator

Hi simonz,

Welcome to GRACE. I’m sorry to hear of the progression of your wife’s cancer. Although we can’t directly advise you which particular treatment to choose, we can provide some thoughts about the factors that you and your wife might consider in making that decision.

First, it’s important to note that although every patient hopes that their initial treatment will produce major shrinkage, with stage IV lung cancer that is often not possible. But a treatment may keep the cancer from growing further, an outcome we call “stable disease”, which is a good (even if not the best) result for metastatic lung cancer.What is not clear from your post is whether your wife’s cancer, after the initial shrinkage on Tagrisso, continued to grow significantly. If so, there was certainly no reason to continue Tagrisso. But if the disease was stable, then continuing Tagrisso until meaningful progression was seen would have been a reasonable option. A well-tolerated targeted therapy such as Tagrisso is often continued even in the face of slow progression.

One of the options for treatment of metastatic lung cancer is immunotherapy, but clinical trials have shown that the response rate for patients with activating EGFR mutations is quite low. As a result, most oncologists in this situation would favor standard chemotherapy. While chemo can produce troublesome side effects, in recent years less toxic chemo agents have been developed, and the ability to keep treatment side effects under control has greatly improved. One of those recent drugs for non-squamous lung cancer is Alimta (pemetrexed), which many doctors feel is the best-tolerated therapy for most patients.

I hope that your wife can have a good discussion with her oncologist and select a treatment plan with which she is comfortable. In addition, when a patient reaches a decision point such as this, a second opinion with another oncologist is often a good choice.

Best to you and your wife.

Forum moderator

Jul 2008 Wife Liz (51/never smoker) Dx Stage IV NSCLC EGFR exon 19
4 cycles Carbo/alimta, 65% shrinkage
Tarceva maintenance
Mar 2010 progression, added Alimta, stable
Sep 2010 multiple brain mets, WBR
Oct 2010 large pericardial effusion, tamponade
Jan 2011 progression, start abraxane
Jun 2011-New liver, brain mets, add Tarceva
Oct 2011-Dx Leptomeningeal carcinomatosis; pulsed Tarceva
At rest Nov 4 2011
Since then: http://cancergrace.org/blog/jim-and-lisa

Viewing 2 posts - 1 through 2 (of 2 total)

You must be logged in to reply to this topic.